Skip to main content

InteRNA, Cenix Ink miRNA Deal

NEW YORK (GenomeWeb News) – Dutch firm InteRNA Technologies and German firm Cenix BioScience today said that they will collaborate on screening assays for miRNAs and therapeutic targets for cancer.
 
Cenix will use InteRNA’s lentiviral-based miRNA overexpression library in high-throughput screening assays in combination with high-content, multi-parametric phenotypic analyses to determine the biological role of individual miRNAs and to identify cancer drug targets.
 
“Cenix’s unique expertise on small RNA-based high-throughput screening and phenotypic analyses will be instrumental in our discovery programs”, Roel Schaapveld, chief operating officer of InteRNA Technologies, said in a statement.
 
Financial and other terms of the collaboration were not disclosed.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.